Consun Pharmaceutical Group Management
Management criteria checks 4/4
Consun Pharmaceutical Group's CEO is Meng An, appointed in Jan 2024, has a tenure of 1.33 years. total yearly compensation is CN¥22.12M, comprised of 5% salary and 95% bonuses, including company stock and options. directly owns 3.97% of the company’s shares, worth $42.17M. The average tenure of the management team and the board of directors is 4.5 years and 4.2 years respectively.
Key information
Meng An
Chief executive officer
CN¥22.1m
Total compensation
| CEO salary percentage | 4.97% |
| CEO tenure | 1.3yrs |
| CEO ownership | 4.0% |
| Management average tenure | 4.5yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | CN¥22m | CN¥1m | CN¥910m |
| Sep 30 2024 | n/a | n/a | CN¥873m |
| Jun 30 2024 | n/a | n/a | CN¥836m |
| Mar 31 2024 | n/a | n/a | CN¥810m |
| Dec 31 2023 | CN¥20m | CN¥1m | CN¥785m |
| Sep 30 2023 | n/a | n/a | CN¥759m |
| Jun 30 2023 | n/a | n/a | CN¥734m |
| Mar 31 2023 | n/a | n/a | CN¥708m |
| Dec 31 2022 | CN¥17m | CN¥1m | CN¥683m |
| Sep 30 2022 | n/a | n/a | CN¥660m |
| Jun 30 2022 | n/a | n/a | CN¥636m |
| Mar 31 2022 | n/a | n/a | CN¥613m |
| Dec 31 2021 | CN¥14m | CN¥670k | CN¥590m |
Compensation vs Market: Meng's total compensation ($USD3.08M) is about average for companies of similar size in the US market ($USD3.98M).
Compensation vs Earnings: Meng's compensation has been consistent with company performance over the past year.
CEO
Meng An (53 yo)
Mr. Meng An serves as Executive Chairman of the Board at Consun Pharmaceutical Group Limited since July 9, 2021 and serves a sits Chief Executive Officer from January 17, 2024. Mr. An being the Chairman of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Chairman | 1.3yrs | CN¥22.12m | 3.97% $ 42.2m | |
| Chief Financial Officer | less than a year | CN¥200.00k | no data | |
| Chief Scientist & Executive Director | 4.5yrs | CN¥742.00k | no data | |
| Assistant President | 5.3yrs | no data | no data | |
| Executive Director | less than a year | no data | no data | |
| Company Secretary | 11.1yrs | no data | no data | |
| Chairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd | 4.5yrs | no data | no data | |
| Chairman & GM of Consun Pharmaceutical (Horgos) Co. | 4.5yrs | no data | no data |
Experienced Management: CPHG.F's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Chairman | 4.2yrs | CN¥22.12m | 3.97% $ 42.2m | |
| Chief Scientist & Executive Director | 12.4yrs | CN¥742.00k | no data | |
| Executive Director | less than a year | no data | no data | |
| Chairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd | 4.5yrs | no data | no data | |
| Chairman & GM of Consun Pharmaceutical (Horgos) Co. | 4.5yrs | no data | no data | |
| Independent Non-Executive Director | 11.4yrs | CN¥200.00k | no data | |
| Independent Non-executive Director | less than a year | no data | no data | |
| Non-Executive Director | 3.8yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | CN¥102.00k | no data |
Experienced Board: CPHG.F's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 21:32 |
| End of Day Share Price | 2025/04/04 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Consun Pharmaceutical Group Limited is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fangqi Dai | China Merchants Securities (HK) Co., Ltd |
| null null | CMB International Securities Limited |
| Trina Chen | Credit Suisse |